Open Medicine · Published 2026-01-01 · DOI 10.1515/med-2026-1416
Chemoradiotherapy (CRT) alone shows limited efficacy in improving outcomes for metastatic colorectal cancer (mCRC) patients. This study aimed to comprehensively evaluate the survival benefits of combining CRT with immunotherapy (CRT + IMT) in this population.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →